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 Abstract 
Objective—Screening for prostate cancer using prostate-specific antigen (PSA) 
tests is common but remains controversial. Total PSA using thresholds of 4.0 and 
2.5 ng/mL has been used for screening men. In addition, the percent free PSA (free 
PSA/total PSA x 100%) using thresholds of less than 25% and 15% have been 
proposed for use in screening for prostate cancer in conjunction with the total PSA. 
The distributions of total PSA, free PSA, and percent free PSA, which vary with 
age and race-ethnicity among American men, would help determine the burden of 
screening using different thresholds of PSA tests. 
Methods—PSA tests were performed on serum samples from men age 40 years 
and older (n= 2,546) who participated in the 2001–04 National Health and Nutrition
Examination Survey (NHANES). Total, free and percent free PSA were estimated 
for Mexican American, non-Hispanic white, and non-Hispanic black men. 
Results—About 6.2%, (95% confidence interval, 95% CI: 5.2–7.2%), 
corresponding to an estimated 3.6 million (95% CI: 3.0–4.2 million) men 40 years 
of age and older, had a total PSA of greater than or equal to 4.0 ng/mL. 
Approximately 3.6% (95% CI: 1.8–6.2%) of Mexican American men, 6.2% (95% 
CI: 5.1–7.6%) of non-Hispanic white men, and 7.8% (95% CI: 5.2–11.1 ) of 
non-Hispanic black men had total PSA of 4.0 ng/mL or more. Approximately 13.1 
(95% CI: 11.7–14.5%) of men 40 years of age and older had total PSA greater than 
or equal to 2.5 ng/mL. For men with total PSA less than 2.5 ng/mL, 23.1% (95% 
CI: 21.0–25.3%) had a percent free PSA between 15% and 25%, and 5.0% had free 
PSA (95% CI: 3.9–6.4%) less than or equal to 15%. 
Conclusions—The effect of lowering the total PSA thresholds increases the 
number of U.S. men who would be referred for screening for prostate cancer. Total 
and free PSA increased with age in Mexican American, non-Hispanic white, and 
non-Hispanic black men. Information about the distribution of total, free, and 
percent free PSA will help guide public health policy in screening for prostate 
cancer. 
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Prostate cancer screening using 
prostate-specific antigen (PSA) is 
common, but remains controversial even 
after 20 years since its introduction 
(1,2). PSA screening issues include 
whether to conduct screening, what age 
to begin screening, what PSA threshold 
to use before recommending a prostate 
biopsy, and what age to stop screening. 
The U.S. Preventive Services Task Force 
has concluded that there is insufficient 
evidence to recommend for or against 
routine prostate cancer screening 
because it is unclear if the risks 
outweigh the benefits for screening for 
prostate cancer (3). However, the 
American Cancer Society (4) and 
American Urological Association (5) 
recommend offering information about 
screening for average-risk men 
beginning at 50 years of age. Also, they 
recommend offering information about 
screening at age 40 if men are at higher 
risk, such as African American men or 
men who have a family history of 
prostate cancer. In general, a prostate 
biopsy is highly recommended for total 
PSA values of 10 ng/mL or higher. For 
total PSA values between 4 and 10 
ng/mL, a prostate biopsy is preferred, 
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has been suggested (1). The percent free 
PSA has also been recommended as an 
adjunct test for certain total PSA values 
to better discriminate whether men are 
more or less likely to develop prostate 
cancer. A lower percent free PSA is 
suggestive of prostate cancer. The 
threshold for percent free PSA has 
generally been less than 25% with some 
studies suggesting a threshold of less 
than 15% (6–8). Guidelines support 
discussing the risk and benefits of 
prostate cancer screening with men 
(3–5). 
Population-based U.S. data on the 
distribution of PSA by age and race-
ethnicity are helpful to both policy 
makers and clinicians. In this report, 
data from NHANES 2001–04 on the 
distributions of total, free, and percent 
free PSA for all males 40 years and 
older and for Mexican Americans, 
non-Hispanic white, and non-Hispanic 
black men are presented. Previous 
reports using the NHANES 2001–02 
data have been published (9–11). 
Saraiya et al. provided race- and 
ethnic-specific data on median total PSA 
and percent free PSA values and 
presented modeling data examining the 
relationship of age and PSA tests (9). 
Lowering the total PSA threshold values 
would increase the number of men to be 
screened and thus have a significant 
impact on the burden of screening. 
Saraiya reported that 1–2 million men 
50–69 years of age would have a total 
PSA value greater than 4 ng/mL and 
1–3 million would have a PSA value 
between 2.5 and 4.0 ng/mL. Using 
2001–02 data, Welch (10) similarly 
reported the number of men in the 
United States above certain PSA 
thresholds by 10-year age categories and 
compared this with the number of men 
projected to die from prostate cancer 
using incidence data from the 
Surveillance, Epidemiology, and End 
Results program of the National Cancer 
Institute (12). Porter used data from 
NHANES 2001–02 and the Prostate 
Cancer Prevention Trial (13) data to 
estimate the prevalence of biopsy 
detectable prostate cancer in men 62–85 
years of age with a total PSA less than 
or equal to 4 ng/mL (11). The addition of NHANES 2003–04 
data used in this report allows for more 
precise estimates of the distribution of 
total, free, and percent free PSA values. 
PSA estimates among all men 40 years 
of age and older and non-Hispanic 
whites 80 years of age and older are 
provided. Also, estimates of percent free 
PSA less than or equal to 15% for 
various total PSA thresholds by age 
groups are presented. 
Methods 
Study population and sample 
design 
The National Health and Nutrition 
Examination Survey (NHANES) 
conducted in 2001–04 is a cross-
sectional, nationally representative 
survey of the civilian 
noninstitutionalized population of the 
United States. The procedures for 
selecting the sample and conducting the 
interviews and examinations for 
NHANES 2001–04 have been described 
(14,15). The NHANES design is a 
stratified, multistage, probability sample. 
This multistage sample is based on a 
selection of counties, blocks, 
households, and persons within 
households. NHANES categorizes 
race-ethnicity as non-Hispanic white, 
non-Hispanic black, Mexican American, 
and other persons (other Hispanics and 
all others) (16). Because the number of 
participants was small in the ‘‘other’’ 
category, estimates by race-ethnicity 
were restricted to non-Hispanic white 
persons, non-Hispanic black persons, 
and Mexican Americans. The analysis of 
all men 40 years and older included the 
‘‘other’’ race-ethnicity group. Race-
ethnicity categories are based on 
self-reported data. Mexican American 
persons, non-Hispanic black persons, 
and adults 60 years and older were 
over-sampled. 
Men ages 40 years and older were 
eligible for PSA testing consisting of 
measured total and free PSA. Percent 
free PSA was calculated as free 
PSA/total PSA x 100%. For NHANES 
2001–04, 4,533 men aged 40 years or 
older were eligible to participate in the 
survey, of whom 3,326 (73.4%) were 
interviewed and 3,108 (68.6%) were interviewed and underwent physical 
examination. After these men received 
general information about the PSA test 
from the examining NHANES 
physician, they were offered the 
opportunity to be tested. Of these 3,108 
eligible men, 257 (8.3%) refused or did 
not give permission for the PSA test. In 
addition, men were excluded from PSA 
testing if they reported, refused to 
answer, or did not know if they had 
procedures or conditions that could alter 
PSA results. These exclusion criteria 
were current infection or inflammation 
of the prostate gland, digital rectal exam 
in the past week, prostate biopsy in the 
past 30 days, cystoscopy in the past 30 
days, or history of prostate cancer. An 
additional 231 (7.4%) had one or more 
of the exclusion criteria that could affect 
PSA levels. Also, 74 (2.4%) of eligible 
men had missing PSA values. Hence, 
2,546 of 3,108 or 81.9% of all examined 
men ages 40 years and older 
participated in the NHANES prostate-
specific antigen testing. 
Collection and storage of 
samples and laboratory 
methods 
As part of the exam, blood samples 
were drawn by venipuncture, 
centrifuged, and the sera frozen at 
–20˚C within 1 hour of the phlebotomy. 
Within 1 week, the frozen specimens 
were sent on dry ice to the University of 
Washington Medical Center, Department 
of Laboratory Medicine, Immunology 
Division Laboratory (Seattle, WA), 
where they were kept at –70˚C until 
analyzed. The PSA values were 
determined using the Hybritech total 
PSA (17) and Hybritech free PSA 
monoclonal antibody (18) assays 
(Hybritech, San Diego, CA) on the 
Beckman Coulter Access analyzer 
(Fullerton, CA). The total PSA method 
is a two-site immunoenzymatic 
‘‘sandwich’’ assay. The sample is mixed 
with mouse monoclonal anti-PSA 
alkaline phosphatase conjugate and 
paramagnetic particles coated with a 
second mouse monoclonal anti-PSA 
antibody. The PSA in the sample binds 
to the immobilized monoclonal anti-PSA 
on the solid phase while the monoclonal 
anti-PSA conjugate reacts with a 
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NOTE: All race-ethnicity groups had significant age effects (p<0.001). The age by race-ethnicity interaction was 
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Figure 1. Total PSA versus age by race-ethnicity different antigenic site on the PSA. 
Separation in a magnetic field and 
washing removes material not bound to 
the solid phase. A chemiluminescent 
substrate is added and the complex is 
measured with a luminometer. The free 
PSA assay is also a two-site 
immunoenzymatic ‘‘sandwich’’ assay. It 
is similar to the Hybritech total PSA but 
uses a monoclonal anti-free PSA 
alkaline phosphatase conjugate and a 
mouse monoclonal anti-free PSA 
antibody. 
The total PSA test had a coefficient 
of variation of less than 4.8% for quality 
control pool means with a range of 0.16 
to 22.32 ng/mL. The free PSA test had a 
coefficient of variation of less than 5.5% 
for quality control pool means with a 
range of 0.59 to 4.77 ng/mL. 
Statistical analysis 
Distributions of total, free, and 
percent free PSA for NHANES 2001–04 
were estimated for all males 40 years 
and older, and by age groups for 
Mexican American, non-Hispanic white, 
and non-Hispanic black persons 
(Tables 1–3). Age was stratified as 
40–49, 50–59, 60–69, and 70 years and 
older. There were sufficient sample sizes 
to determine PSA levels for all males 
and non-Hispanic white persons for the 
age groups 70–79 and 80 years and 
older. The mean, standard error of the 
mean, 5th, 10th, 25th, 50th, 75th, 90th, 
and 95th percentiles were determined 
for each race-ethnicity by age group. 
The 95% confidence intervals for the 
percentiles were determined using the 
Woodruff method (19). 
Proportions at different total PSA 
threshold values were estimated for all 
men and by age and race-ethnicity 
(Table 4). The PSA threshold values 
were based on the Prostate Cancer 
Prevention Trial (13). The 95% 
confidence intervals were calculated as 
exact limits based on the binomial 
distribution. Some proportion estimates 
did not meet standards of reliability and 
precision as determined by the relative 
standard error of the proportion (SE of 
the proportion/proportion x 100%) 
greater than 30%. 
The distribution of percent free PSA 
by total PSA was estimated for age groups (Table 5). The percent free PSA 
was categorized as less than or equal to 
15%, greater than 15%–25%, and 
greater than 25% when sufficient sample 
size and statistical precision were 
present. Otherwise, the percent free PSA 
was dichotomized as greater than or less 
than or equal to 25%. National estimates 
of the number of men in each PSA 
group were determined by multiplying 
the percentages and confidence intervals 
by the average population estimates 
from the 2001 to 2004 Current 
Population Survey. 
Three linear regression models were 
fit to determine the relationship between 
total, free, and percent free PSA and age 
(Figures 1–3). Age was transformed in 
each model using restricted cubic spline 
functions to allow for nonlinearity (20). 
All models were adjusted for race-
ethnicity and examined for interaction 
between age and race-ethnicity to 
determine if the relationship between 
age and each PSA measure was similar 
across race-ethnicity groups. The PSA 
measures were log transformed in all 
models because of nonnormality. The 
predicted PSA values were then back 
transformed to the original scale. Due to 
the small number of denominator 
degrees of freedom, the F-statistic with 
Satterthwaite correction for the degrees 
of freedom was used to test significance. Variance estimates were calculated 
using Taylor series linearization (21). 
Sample weights, which account for the 
differential probabilities of selection, 
nonresponse, and noncoverage were 
incorporated into the variance estimation 
process. Most statistics were generated 
using SUDAAN version 9.0 (Research 
Triangle Institute, Research Triangle 
Park, NC) and SAS version 9.1 (SAS 
Institute, Inc., Cary, NC). The survey 
package version 3.4.2 in R (22,23) 
version 2.2.1 (Free Software Foundation, 
Inc., Boston, MA) was used to 
determine the percentiles and confidence 
intervals for percentiles using the 
Woodruff method (19). Ninety-five 
percent confidence intervals for 
percentiles and proportions are shown in 
parenthesis in the text. 
Results 
Distribution of PSA tests 
In all males and each of the 
race-ethnicity groups, the mean, median, 
75th, 90th, and 95th percentiles for total 
PSA increased by age group (Table 1). 
Overall, the median total PSA was 0.70 
(0.70–0.80) ng/mL for 40–49 years and 
increased to 2.10 (1.70–2.30) ng/mL for 
men 80 years or older. For men 70 years 
and older, the total PSA at the 75th 
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4 Advance Data No. 379 + December 4, 2006percentile were 3.45 (2.70–4.39), 3.40
(3.10–3.90), and 5.40 (4.51–6.10) ng/mL
for Mexican American, non-Hispanic
white, and non-Hispanic black persons,
respectively. For all men and for each
race-ethnicity group, the mean, median,
75th, 90th, and 95th percentiles for free
PSA also increased with each older age
group (Table 2). For all men, the median
free PSA ranged from 0.22 (0.20–0.23)
ng/mL for men 40–49 years to 0.58
(0.50–0.72) ng/mL for men 80 years and
older. For men 70 years and older, the
free PSA at the 75th percentile was 0.67
(0.59–0.92), 0.88 (0.78–0.97), and 1.51
(0.77–1.75) ng/mL for Mexican
American, non-Hispanic white, and
non-Hispanic black persons,
respectively. In contrast to the pattern
seen with total and free PSA with age,
the median percent free PSA was
somewhat constant across the age
groups within the race-ethnicity groups
(Table 3). The median percent free PSA
ranged from 28.0% to 30.0% for the
different age groups. Non-Hispanic
black persons showed a decreasing
percent free PSA with older age. At the
90th percentile, non-Hispanic black
persons had a percent free PSA of
50.0% (45.0–56.0) for men 40–49 years
and 42.0% (38.8–44.6) for men 70 years
and older.
Relation of PSA to age
Regression analysis showed that
total PSA increased with age (Figure 1),
but the relationship between age and
total PSA varied significantly across the
three race-ethnicity groups. The total
PSA increased more steeply with age
among non-Hispanic black persons
compared with non-Hispanic white and
Mexican American persons. The free
PSA also showed an increase with age
for the three race-ethnicity groups,
however, the age by race-ethnicity
interaction was not significant
(Figure 2). There was a significant
nonlinear relationship between percent
free PSA and age among non-Hispanic
black persons (Figure 3). Increasing age
was associated with decreasing percent
free PSA for non-Hispanic black men
under 60 years of age.PSA threshold values
The proportion of men who had
total PSA levels at or above different
thresholds is seen in Table 4. The
proportions equal to or above a total
PSA threshold increased by age in men
40 years and older in each race-ethnicity
group. Overall, 6.2% (5.2–7.2) of men
over 40 years had total PSA greater than
or equal to 4 ng/mL and 13.1%(11.7–14.5) were greater than 2.5
ng/mL, the lower suggested screening
threshold. For men 80 years and older,
29.0% (22.4–36.4) had PSA levels
greater than or equal to 4 ng/mL.
Overall, total PSA was greater than or
equal to 4 ng/mL for 3.6% (1.8–6.2),
6.2% (5.1–7.6), and 7.8% (5.2–11.1) for
Mexican American, non-Hispanic white,
and non-Hispanic black men,
respectively. Also, 1.1% (0.7–1.6) of
5 Advance Data No. 379 + December 4, 2006 men had a total PSA threshold greater 
than or equal to 10 ng/mL. For men 80 
years and older, 6.3% (3.3–10.8) had 
total PSA greater than or equal to 10 
ng/mL. 
The distribution of percent free PSA 
thresholds by total PSA thresholds for 
different age groups is seen in Table 5. 
In general, as age increased, the 
percentage of men with percent free 
PSA less than or equal to 25% also 
increased across the range of total PSA 
values. For example, of men ages 40–49 
years, 6.5% (4.8–8.6) had a total PSA 
level less than 2.5 ng/mL and a percent 
free PSA less than or equal to 15%, and 
25.3% (21.3–29.7) had a total PSA level 
less than 2.5 ng/mL and a percent free 
PSA of greater than 15%–25%. Of men 
40–49 years of age, 2.3% (1.3–3.6) had 
a total PSA 2.5 to less than 4.0 ng/mL 
and a percent free PSA less than or 
equal to 25%, or an estimated 484,000 
men. There were 6.8% (4.0–10.5) of 
men ages 70–79 years with a PSA of 
2.5 to less than 4.0 ng/mL and a percent 
free PSA less than or equal to 25%. In 
this age group, 9.1% (5.6–13.6) of men 
had a PSA of 4.0 to less than 10 ng/mL 
and a percent free PSA less than or 
equal to 25%, representing 
approximately 618,000 men. All men 80 
years and older with a total PSA greater 
than or equal to 10 ng/mL had free 
percent PSA less than or equal to 25%. 
Discussion 
The American Cancer Society (4) 
and the American Urological 
Association (5) recommend offering 
information regarding the risks and 
benefits of total PSA screening and 
digital rectal examination. In addition, 
the use of percent free PSA (free/total 
PSA), complexed PSA, PSA velocity, 
and PSA density with ultrasound of the 
prostate have been proposed as 
additional tests to enhance the 
specificity of total PSA (24). Recently, 
serum proteomics patterns have been 
used to detect prostate cancer (25). 
Previous reports on total and percent 
free PSA using the NHANES 2001–02 
data have been published (9–11). 
The distribution of the free PSA for 
NHANES was not reported previously. 
The age-specific distribution of free PSA generally followed the same age 
pattern as total PSA (Tables 1,2). With 
increasing age, both free and total PSA 
levels increased for all race-ethnicity 
groups (Figures 1,2). Non-Hispanic 
blacks had steeper increases in total 
PSA with increasing age compared with 
non-Hispanic white and Mexican 
American persons (interaction of age by 
race-ethnicity, p<0.05). 
The proportion of men at or above 
various total PSA thresholds for 
different race-ethnicity groups were 
estimated (Table 4). Age-specific 
estimates for total PSA thresholds of 1, 
2, 2.5, 3, 4, 6, 8, and 10 ng/mL are 
reported for the first time for Mexican 
American, non-Hispanic white, and 
non-Hispanic black men. Estimates for 
some threshold values could not be 
reported due to limitations in sample 
size or statistical precision. 
Finally, estimates of percent free 
PSA less than or equal to 15% for 
various total PSA thresholds by age 
groups are presented for the first time 
(Table 5). The threshold for percent free 
PSA has been less than 25%, but a 
threshold of less than 15% has been 
suggested for follow-up of elevated total 
PSA levels. For total PSA of 2.5 to less 
than 4.0 ng/mL, 1.5% (1.0–2.2) of men 
40 years and older had percent free PSA 
less than or equal to 15%, and 2.9% 
(2.3–3.7) had percent free PSA greater 
than 15%– 25%. The percent free PSA 
less than or equal to 15% generally 
increased with age. The range of percent 
free PSA less than or equal to 15% was 
from 8.4% (6.4–10.7) of men ages 
40–49 to 12.9% (8.0–19.3) for men ages 
80 years and older. 
The limitation of NHANES data is 
that it is cross-sectional and does not 
allow for the diagnosis and outcome of 
prostate cancer. Also, approximately 
20% of all examined men greater than 
or equal to 40 years did not participate 
in PSA testing. Men with missing PSA 
test values were older and were more 
likely to be non-Hispanic black. 
However, the distribution of total, free, 
and percent free PSA in men ages 40 
and older using NHANES 2001–04 data 
should help guide policies of screening 
of prostate cancer. Further collection of 
PSA test data will allow for further 
stratification of the PSA data and increase the precision of the 
distributions among sample persons. 
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Table 1. Distribution of total PSA (ng/mL) 
Percentiles (95% confidence intervals) of distribution 
Geometric 
Age and race-ethnicity Number mean (SE) 5  10  25  50  75  90  95  
All men1 
40 years and older . . . . . . .  2,546  0.94  (0.02)  0.30  (0.20–0.30) 0.40 (0.30–0.40) 0.50 (0.50–0.60) 0.90 (0.80–0.90) 1.50 (1.40–1.60) 2.90 (2.70–3.20) 4.40 (4.00–4.90) 
40–49 years . . . . . . . . . .  747  0.73  (0.02)  0.30  (0.20–0.30) 0.30 (0.30–0.40) 0.50 (0.50–0.50) 0.70 (0.70–0.80) 1.00 (1.00–1.10) 1.60 (1.40–1.80) 2.20 (1.80–2.60) 
50–59 years . . . . . . . . . .  546  0.92  (0.03)  0.30  (0.20–0.30) 0.40 (0.30–0.40) 0.50 (0.50–0.60) 0.90 (0.80–1.00) 1.50 (1.37–1.70) 2.43 (2.20–2.70) 3.60 (2.82–4.40) 
60–69 years . . . . . . . . . .  555  1.13  (0.05)  0.24  (0.20–0.30) 0.40 (0.30–0.40) 0.60 (0.50–0.70) 1.10 (1.00–1.30) 2.09 (1.90–2.30) 3.49 (3.20–4.00) 5.20 (4.40–5.60) 
70 years and older . . . . . .  698  1.66  (0.06)  0.30  (0.20–0.40) 0.40 (0.30–0.50) 0.80 (0.80–0.90) 1.60 (1.50–1.80) 3.50 (3.20–3.90) 6.20 (5.60–7.04) 8.94 (7.60–10.72) 
70–79 years . . . . . . . . .  447  1.56  (0.08)  0.30  (0.20–0.40) 0.40 (0.40–0.50) 0.80 (0.70–0.80) 1.50 (1.40–1.70) 3.20 (2.90–3.70) 5.44 (4.99–6.51) 8.02 (6.38–10.00) 
80 years and older . . . . .  251  1.98  (0.17)  0.20  (0.10–0.30) 0.40 (0.20–0.50) 1.09 (0.70–1.25) 2.10 (1.70–2.30) 4.38 (3.48–5.60) 7.69 (6.50–10.80) ** 
Mexican American 
40 years and older . . . . . . .  485  0.91  (0.04)  0.30  (0.30–0.40) 0.40 (0.40–0.50) 0.60 (0.50–0.60) 0.80 (0.80–0.90) 1.30 (1.27–1.40) 2.47 (1.98–3.02) 3.60 (2.90–4.50) 
40–49 years . . . . . . . . . .  166  0.78  (0.05)  0.40  (0.10–0.40) 0.40 (0.30–0.50) 0.50 (0.50–0.60) 0.71 (0.70–0.80) 1.10 (1.00–1.20) 1.40 (1.30–1.70) 1.87 (1.41–3.56) 
50–59 years . . . . . . . . . .  74  0.95  (0.06)  0.30  (0.20–0.45) 0.40 (0.30–0.50) 0.60 (0.50–0.60) 0.90 (0.63–1.00) 1.60 (1.30–1.87) 2.48 (1.96–3.60) 3.16 (2.47–4.50) 
60–69 years . . . . . . . . . .  140  1.08  (0.10)  0.29  (0.10–0.30) 0.35 (0.28–0.40) 0.52 (0.40–0.70) 1.00 (0.80–1.30) 1.90 (1.60–2.30) *3.39 (2.80–7.30) ** 
70 years and older . . . . . .  105  1.68  (0.13)  0.40  (0.10–0.50) 0.52 (0.40–0.60) 0.90 (0.71–1.10) 1.60 (1.30–1.90) 3.45 (2.70–4.39) 4.85 (3.91–7.99) ** 
Non-Hispanic white 
40 years and older . . . . . . .  1,476  0.94  (0.02)  0.30  (0.20–0.30) 0.40 (0.30–0.40) 0.50 (0.50–0.60) 0.90 (0.80–0.90) 1.60 (1.40–1.70) 2.90 (2.60–3.20) 4.30 (4.00–4.90) 
40–49 years . . . . . . . . . .  363  0.74  (0.03)  0.30  (0.20–0.30) 0.30 (0.30–0.40) 0.50 (0.50–0.50) 0.70 (0.70–0.80) 1.10 (1.00–1.20) 1.60 (1.50–1.90) 2.37 (1.84–2.70) 
50–59 years . . . . . . . . . .  328  0.88  (0.04)  0.30  (0.10–0.30) 0.40 (0.30–0.40) 0.50 (0.40–0.60) 0.90 (0.70–0.90) 1.40 (1.30–1.70) 2.40 (2.20–2.70) 3.11 (2.60–4.83) 
60–69 years . . . . . . . . . .  287  1.13  (0.06)  0.24  (0.19–0.30) 0.40 (0.30–0.40) 0.60 (0.50–0.70) 1.10 (1.00–1.30) 2.10 (1.90–2.40) 3.40 (3.20–4.05) 4.98 (4.11–5.59) 
70 years and older . . . . . .  498  1.63  (0.07)  0.30  (0.20–0.40) 0.40 (0.30–0.50) 0.80 (0.70–0.90) 1.70 (1.50–1.80) 3.40 (3.10–3.90) 6.00 (5.30–6.80) 8.66 (7.00–11.06) 
70–79 years . . . . . . . . .  295  1.54  (0.09)  0.30  (0.20–0.40) 0.40 (0.40–0.50) 0.80 (0.70–0.80) 1.50 (1.40–1.80) 3.20 (2.80–3.70) 5.30 (4.52–6.21) 7.01 (6.00–10.28) 
80 years and older . . . . .  203  1.89  (0.16)  0.21  (0.10–0.30) 0.40 (0.23–0.50) 1.00 (0.67–1.25) 1.90 (1.70–2.30) 4.07 (3.30–5.52) 7.65 (6.40–10.80) *10.80 (8.40–22.46) 
Non–Hispanic black 
40 years and older . . . . . . .  435  0.99  (0.05)  0.30  (0.20–0.40) 0.40 (0.37–0.40) 0.50 (0.50–0.60) 0.90 (0.80–1.00) 1.60 (1.40–1.85) 2.80 (2.35–4.50) 5.45 (4.50–7.70) 
40–49 years . . . . . . . . . .  174  0.74  (0.04)  0.30  (0.10–0.40) 0.40 (0.30–0.40) 0.50 (0.40–0.60) 0.70 (0.70–0.80) 1.10 (1.00–1.20) 1.73 (1.34–2.00) 2.00 (1.80–2.59) 
50–59 years . . . . . . . . . .  101  1.04  (0.10)  0.40  (0.20–0.40) 0.40 (0.40–0.50) 0.50 (0.50–0.68) 0.80 (0.75–1.10) 1.80 (1.30–2.20) 2.80 (2.25–4.79) ** 
60–69 years . . . . . . . . . .  99  1.54  (0.17)  0.30  (0.10–0.40) 0.40 (0.30–0.56) 0.79 (0.50–1.00) 1.50 (1.20–1.77) 2.70 (2.00–3.79) *5.77 (3.70–11.88) 10.30 (7.47–14.28) 
70 years and older . . . . . .  61  2.16  (0.42)  **  *0.40  (0.10–0.62) 0.89 (0.50–1.20) ** 5.40 (4.51–6.10) ** ** 
* Relative standard error 30–40 percent.

** Relative standard error greater than 40 percent, and the value was suppressed.

1All men includes sample persons of ‘‘other’’ race-ethnicity, but they are not shown separately.
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Table 2. Distribution of free PSA (ng/mL) 
Percentiles (95% confidence intervals) of distribution 
Geometric 
Age and race–ethnicity Number mean (SE) 5  10  25  50  75  90  95  
All men1 
40 years and older . . . . . . .  2,546  0.27  (0.01)  0.08  (0.07–0.09) 0.11 (0.10–0.12) 0.17 (0.16–0.18) 0.26 (0.25–0.27) 0.41 (0.38–0.44) 0.67 (0.63–0.73) 0.97 (0.88–1.07) 
40–49 years . . . . . . . . . .  747  0.21  (0.01)  0.08  (0.07–0.09) 0.10 (0.09–0.12) 0.14 (0.13–0.16) 0.22 (0.20–0.23) 0.31 (0.29–0.34) 0.43 (0.40–0.49) 0.51 (0.48–0.59) 
50–59 years . . . . . . . . . .  546  0.25  (0.01)  0.09  (0.07–0.10) 0.12 (0.09–0.13) 0.17 (0.16–0.18) 0.24 (0.23–0.26) 0.39 (0.35–0.46) 0.57 (0.54–0.63) 0.73 (0.66–0.79) 
60–69 years . . . . . . . . . .  555  0.32  (0.01)  0.09  (0.06–0.10) 0.12 (0.10–0.14) 0.19 (0.18–0.23) 0.32 (0.30–0.35) 0.51 (0.47–0.55) 0.82 (0.74–0.94) 1.08 (0.99–1.24) 
70 years and older . . . . . .  698  0.47  (0.02)  0.09  (0.06–0.12) 0.15 (0.12–0.18) 0.27 (0.25–0.29) 0.46 (0.43–0.50) 0.89 (0.81–0.98) 1.56 (1.43–1.69) 2.10 (1.87–2.40) 
70–79 years . . . . . . . . .  447  0.44  (0.02)  0.10  (0.06–0.13) 0.15 (0.12–0.19) 0.26 (0.23–0.28) 0.42 (0.38–0.46) 0.82 (0.71–0.91) 1.40 (1.19–1.56) 1.76 (1.57–2.23) 
80 years and older . . . . .  251  0.56  (0.04)  0.07  (0.04–0.11) 0.13 (0.10–0.17) 0.32 (0.24–0.36) 0.58 (0.50–0.72) 1.12 (0.93–1.35) 1.99 (1.64–2.60) 2.92 (2.09–4.40) 
Mexican American 
40 years and older . . . . . . .  485  0.24  (0.01)  0.08  (0.06–0.10) 0.12 (0.09–0.13) 0.16 (0.15–0.17) 0.23 (0.21–0.24) 0.32 (0.31–0.36) 0.54 (0.49–0.65) 0.72 (0.66–0.96) 
40–49 years . . . . . . . . . .  166  0.21  (0.01)  0.08  (0.05–0.12) 0.12 (0.08–0.15) 0.16 (0.15–0.17) 0.21 (0.19–0.23) 0.28 (0.26–0.30) 0.36 (0.31–0.40) 0.43 (0.39–0.56) 
50–59 years . . . . . . . . .  74  0.23  (0.01)  0.07  (0.04–0.09) 0.09 (0.06–0.13) 0.15 (0.13–0.19) 0.23 (0.20–0.27) 0.33 (0.31–0.38) 0.53 (0.38–0.82) 0.67 (0.54–1.13) 
60–69 years . . . . . . . . .  140  0.29  (0.02)  0.07  (0.04–0.09) 0.10 (0.07–0.13) 0.18 (0.14–0.19) 0.28 (0.24–0.34) 0.50 (0.42–0.62) 0.86 (0.62–1.25) ** 
70 years and older . . . . .  105  0.42  (0.03)  0.10  (0.07–0.13) 0.13 (0.09–0.17) 0.22 (0.18–0.30) 0.42 (0.39–0.53) 0.67 (0.59–0.92) ** ** 
Non–Hispanic white 
40 years and older . . . . . . .  1,476  0.27  (0.01)  0.08  (0.07–0.09) 0.11 (0.10–0.12) 0.17 (0.16–0.18) 0.26 (0.25–0.28) 0.42 (0.39–0.46) 0.70 (0.65–0.75) 0.99 (0.88–1.10) 
40–49 years . . . . . . . . . .  363  0.22  (0.01)  0.08  (0.05–0.09) 0.10 (0.08–0.12) 0.14 (0.13–0.17) 0.22 (0.20–0.25) 0.33 (0.29–0.36) 0.45 (0.41–0.51) 0.53 (0.49–0.67) 
50–59 years . . . . . . . . .  328  0.25  (0.01)  0.08  (0.06–0.10) 0.12 (0.09–0.13) 0.17 (0.15–0.18) 0.24 (0.22–0.26) 0.38 (0.33–0.47) 0.56 (0.51–0.63) 0.72 (0.65–0.80) 
60–69 years . . . . . . . . .  287  0.32  (0.01)  0.09  (0.06–0.10) 0.11 (0.10–0.14) 0.20 (0.17–0.23) 0.32 (0.29–0.35) 0.51 (0.47–0.54) 0.82 (0.71–0.95) 1.07 (0.87–1.30) 
70 years and older . . . . .  498  0.47  (0.02)  0.10  (0.08–0.12) 0.15 (0.12–0.19) 0.27 (0.25–0.29) 0.46 (0.43–0.51) 0.88 (0.78–0.97) 1.49 (1.34–1.60) 2.02 (1.69–2.18) 
70–79 years . . . . . . .  295  0.44  (0.02)  0.10  (0.08–0.14) 0.15 (0.13–0.20) 0.27 (0.24–0.28) 0.43 (0.38–0.46) 0.83 (0.73–0.93) 1.32 (1.18–1.49) 1.63 (1.49–2.16) 
80 years and older . . . 203 0.54 (0.04) 0.08 (0.04–0.11) 0.13 (0.11–0.17) 0.30 (0.24–0.36) 0.56 (0.50–0.69) 1.08 (0.86–1.33) 1.98 (1.58–2.21) 2.60 (2.09–3.27) 
Non–Hispanic black 
40 years and older . . . . . . .  435  0.28  (0.01)  0.10  (0.06–0.11) 0.12 (0.10–0.14) 0.17 (0.15–0.18) 0.26 (0.24–0.28) 0.41 (0.38–0.47) 0.67 (0.58–0.91) 1.22 (0.84–1.61) 
40–49 years . . . . . . . . . .  174  0.22  (0.01)  0.10  (0.05–0.10) 0.10 (0.10–0.12) 0.15 (0.14–0.17) 0.23 (0.21–0.25) 0.31 (0.28–0.34) 0.41 (0.38–0.49) 0.49 (0.45–0.56) 
50–59 years . . . . . . . . .  101  0.29  (0.02)  0.10  (0.07–0.13) 0.13 (0.11–0.15) 0.17 (0.15–0.20) 0.27 (0.23–0.33) 0.42 (0.33–0.60) 0.67 (0.56–1.04) 0.99 (0.67–1.59) 
60–69 years . . . . . . . . .  99  0.41  (0.04)  0.10  (0.05–0.14) 0.14 (0.09–0.19) 0.25 (0.19–0.30) 0.42 (0.34–0.48) 0.66 (0.54–0.76) ** *1.93 (1.16–4.19) 
70 years and older . . . . .  61  0.56  (0.10)  *0.08  (0.04–0.15) 0.15 (0.04–0.19) 0.22 (0.17–0.29) 0.56 (0.33–0.78) 1.51 (0.77–1.75) ** *4.14 (1.76–7.02) 
* Relative standard error 30–40 percent.

** Relative standard error greater than 40 percent, and the value was suppressed.

1All men includes sample persons of ‘‘other’’ race-ethnicity, but they are not shown separately.
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Table 3. Distribution of percent free PSA 
Percentiles (95% confidence intervals) of distribution 
Geometric 
Age and race–ethnicity Number mean (SE) 5  10  25  50  75  90  95  
All men1 
40 years and older . . . . . . .  2,546  28.35  (0.50)  13.0  (12.0–14.0) 16.0 (15.0–17.0) 22.0 (21.0–23.0) 29.0 (28.0–30.0) 39.0 (38.0–40.0) 48.0 (47.0–50.0) 53.0 (52.0–55.6) 
40–49 years . . . . . . . . . .  747  28.94  (0.63)  13.0  (12.0–14.0) 17.0 (14.0–18.0) 22.9 (20.0–23.0) 30.0 (28.0–32.0) 40.0 (38.0–42.0) 49.0 (47.0–50.1) 53.0 (50.1–57.9) 
50–59 years . . . . . . . . . .  546  27.72  (0.54)  13.0  (11.0–14.0) 15.0 (14.0–17.0) 22.0 (20.0–23.0) 28.0 (27.0–29.0) 38.0 (36.0–40.0) 47.8 (45.0–49.9) 53.0 (50.0–59.2) 
60–69 years . . . . . . . . . .  555  28.08  (0.73)  13.0  (12.0–15.0) 16.0 (15.0–18.0) 22.0 (20.0–23.0) 28.0 (27.0–30.0) 38.0 (35.0–40.0) 46.0 (43.0–50.0) 53.0 (50.0–60.0) 
70 years and older . . . . . .  698  28.29  (0.86)  13.0  (8.8–14.0) 15.0 (13.0–17.0) 22.0 (20.0–24.0) 30.0 (28.0–31.0) 39.0 (37.0–40.0) 47.8 (46.0–50.0) 55.0 (51.0–58.0) 
70–79 years . . . . . . . . .  447  28.24  (0.93)  12.5  (11.3–13.0) 15.0 (13.0–17.0) 22.0 (20.0–24.0) 30.0 (28.0–31.6) 38.0 (36.0–40.0) 47.0 (45.2–50.0) 53.0 (50.0–60.0) 
80 years and older . . . . .  251  28.41  (1.10)  13.0  (8.7–14.0) 15.0 (13.0–16.5) 21.0 (18.0–23.0) 30.0 (27.0–33.0) 40.0 (38.5–41.0) 50.0 (46.0–55.0) 57.0 (53.0–58.1) 
Mexican American 
40 years and older . . . . . . .  485  26.14  (0.63)  13.0  (11.0–13.0) 15.0 (13.0–16.0) 20.0 (19.0–21.0) 27.0 (26.0–28.0) 35.0 (33.0–37.4) 43.0 (40.2–48.5) 50.0 (47.0–52.0) 
40–49 years . . . . . . . . . .  166  26.83  (0.87)  13.0  (7.2–14.6) 16.0 (13.0–17.5) 20.0 (19.0–23.0) 28.0 (26.0–30.0) 35.7 (34.0–38.0) 43.0 (40.0–48.5) 47.8 (43.0–58.8) 
50–59 years . . . . . . . . . .  74  24.72  (0.93)  13.0  (11.0–13.0) 13.4 (12.0–17.0) 18.0 (15.9–20.0) 23.0 (21.0–27.0) 32.5 (29.0–39.0) 43.0 (38.7–51.4) 50.0 (43.0–67.0) 
60–69 years . . . . . . . . . .  140  26.84  (1.56)  12.0  (4.0–15.4) 15.7 (11.5–18.0) 20.0 (18.3–22.1) 26.0 (23.0–30.2) 36.0 (32.0–41.5) 46.6 (40.0–60.7) 57.5 (47.2–89.3) 
70 years and older . . . . . .  105  25.02  (0.84)  11.9  (11.0–12.7) 14.0 (11.5–16.0) 20.0 (16.0–21.0) 26.0 (22.8–28.0) 31.0 (30.0–35.1) 41.1 (37.0–50.5) 49.8 (43.9–57.8) 
Non–Hispanic white 
40 years and older . . . . . . .  1,476  28.64  (0.48)  13.0  (12.0–14.0) 16.2 (15.0–17.0) 23.0 (21.7–23.0) 29.0 (28.0–30.0) 39.0 (38.0–40.0) 48.0 (47.0–50.0) 54.0 (53.0–57.0) 
40–49 years . . . . . . . . . .  363  29.18  (0.64)  13.0  (12.0–15.0) 17.0 (15.0–18.0) 23.0 (21.0–23.0) 30.0 (28.0–32.0) 40.0 (38.8–43.0) 49.0 (48.0–52.6) 54.0 (51.0–58.0) 
50–59 years . . . . . . . . . .  328  28.28  (0.56)  13.0  (12.0–14.0) 16.3 (14.0–18.0) 23.0 (21.0–23.0) 28.0 (27.0–30.0) 38.0 (35.0–40.0) 47.3 (43.0–50.0) 54.0 (50.0–60.0) 
60–69 years . . . . . . . . . .  287  27.91  (0.86)  13.0  (11.6–15.0) 16.0 (14.4–18.0) 22.0 (20.0–23.0) 28.0 (26.0–30.0) 38.0 (35.0–40.0) 44.8 (40.0–52.0) 52.5 (47.0–63.9) 
70 years and older . . . . . .  498  28.77  (0.96)  13.0  (7.6–15.0) 15.0 (13.0–17.0) 22.0 (20.0–24.0) 30.0 (28.0–32.0) 39.0 (38.0–41.0) 50.0 (47.0–50.3) 57.0 (52.0–60.0) 
70–79 years . . . . . . . . .  295  28.79  (1.08)  12.3  (9.4–14.0) 15.0 (13.0–18.0) 22.0 (20.0–26.0) 30.0 (28.0–32.8) 39.0 (36.0–41.0) 47.4 (46.0–50.1) 53.6 (50.0–61.2) 
80 years and older . . . . .  203  28.73  (1.22)  13.0  (8.6–14.3) 15.0 (13.0–17.0) 21.0 (18.0–24.0) 30.0 (26.4–33.0) 40.0 (39.0–42.0) 50.0 (47.0–57.0) 57.0 (53.0–61.5) 
Non–Hispanic black 
40 years and older . . . . . . .  435  28.33  (0.67)  12.5  (11.0–13.0) 15.0 (13.0–16.0) 21.0 (19.0–23.0) 30.0 (28.0–33.0) 40.0 (38.0–41.0) 48.0 (46.0–50.0) 54.0 (51.8–56.0) 
40–49 years . . . . . . . . . .  174  29.68  (1.16)  13.0  (11.4–15.0) 16.0 (13.0–18.0) 23.0 (18.9–26.0) 31.0 (27.5–34.0) 41.0 (38.0–43.0) 50.0 (45.0–56.0) 56.0 (52.0–62.1) 
50–59 years . . . . . . . . . .  101  27.63  (0.97)  11.0  (5.1–14.2) 15.3 (10.3–17.7) 21.1 (19.0–23.0) 28.0 (26.4–30.0) 40.0 (37.3–43.0) 48.0 (45.1–51.0) 51.0 (48.0–54.9) 
60–69 years . . . . . . . . . .  99  26.77  (1.60)  10.0  (5.0–12.8) 13.0 (10.0–15.0) 18.0 (15.0–23.0) 29.0 (25.0–33.0) 39.0 (35.6–43.9) 47.8 (42.2–59.2) 54.0 (47.9–88.0) 
70 years and older . . . . . .  61  26.09  (1.17)  10.3  (6.0–12.0) 12.0 (8.7–16.2) 20.0 (17.0–23.3) 29.8 (27.4–32.0) 36.0 (33.0–40.0) 42.0 (38.8–44.6) 43.3 (41.6–48.0) 
1All men includes sample persons of ‘‘other’’ race-ethnicity, but they are not shown separately. 
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Table 4. Percent (95% confidence intervals) of men at different total PSA thresholds 
Age and race–ethnicity Number PSA ≥ 1 ng/mL PSA ≥ 2 ng/mL PSA ≥ 2.5 ng/mL PSA ≥ 3 ng/mL PSA ≥ 4 ng/mL PSA ≥ 6 ng/mL PSA ≥ 8 ng/mL PSA ≥ 10 ng/mL 
All men1 
40 years and older . . . . . . .  2,546  45.1  (42.4–47.9) 17.8 (16.3–19.4) 13.1 (11.7–14.5) 9.5 (8.1–10.9) 6.2 (5.2–7.2) 2.9 (2.2–3.6) 1.7 (1.2–2.2) 1.1 (0.7–1.6) 
40–49 years . . . . . . . . . .  747  31.3  (26.9–35.9) 6.0 (4.1–8.4) 4.2 (2.7–6.3) *2.3 (0.9–5.0) *1.7 (0.6–3.7) ** ** ** 
50–59 years . . . . . . . . . .  546  45.7  (41.0–50.5) 16.7 (13.0–21.1) 10.0 (7.4–13.1) 6.4 (3.9–9.9) 3.8 (2.3–5.9) *1.6 (0.6–3.4) ** ** 
60–69 years . . . . . . . . . .  555  57.6  (51.9–63.2) 27.2 (23.5–31.1) 20.2 (16.8–24.1) 14.9 (12.0–18.1) 8.0 (5.9–10.6) 3.6 (2.2–5.5) 1.9 (0.9–3.4) *1.1 (0.4–2.3) 
70 years and older . . . . . .  698  70.0  (66.4–73.4) 44.0 (40.1–48.0) 36.9 (33.3–40.6) 30.5 (27.1–34.0) 22.0 (19.0–25.3) 11.2 (9.0–13.8) 6.3 (4.3–8.9) 4.1 (2.6–6.1) 
70–79 years . . . . . . . . .  447  67.3  (62.7–71.6) 41.5 (36.8–46.4) 35.1 (30.6–39.7) 28.3 (24.0–32.9) 19.5 (15.5–23.9) 8.8 (5.8–12.8) 5.1 (3.2–7.8) 3.3 (1.6–5.8) 
80 years and older . . . . .  251  77.3  (70.3–83.3) 50.8 (43.3–58.3) 42.0 (34.3–49.9) 36.3 (29.8–43.2) 29.0 (22.4–36.4) 17.7 (13.2–23.0) 9.6 (5.3–15.8) 6.3 (3.3–10.8) 
Mexican American 
40 years and older . . . . . . .  485  42.7  (37.3–48.2) 13.6 (10.5–17.3) 10.2 (6.9–14.4) 6.7 (4.1–10.4) 3.6 (1.8–6.2) *1.4 (0.5–2.8) ** ** 
40–49 years . . . . . . . . . .  166  33.7  (25.4–42.9) *5.3 (2.0–11.1) ** ** ** ** ** ** 
50–59 years . . . . . . . . . .  74  48.1  (36.3–60.0) 17.5 (9.6–28.0) *11.1 (5.0–20.5) ** ** ** ** ** 
60–69 years . . . . . . . . . .  140  50.7  (40.9–60.5) 24.0 (17.2–32.0) 17.6 (10.6–26.5) 15.0 (7.8–25.0) *8.5 (3.2–17.8) ** ** ** 
70 years and older . . . . . .  105  71.8  (62.2–80.2) 40.2 (30.8–50.2) 38.0 (28.3–48.5) 31.2 (21.4–42.5) 18.8 (10.2–30.3) 4.7 (1.5–10.6) ** ** 
Non–Hispanic white 
40 years and older . . . . . . .  1,476  45.4  (42.1–48.7) 18.4 (16.5–20.5) 13.5 (11.7–15.3) 9.6 (8.0–11.4) 6.2 (5.1–7.6) 2.7 (1.9–3.6) 1.5 (1.0–2.3) 1.0 (0.6–1.7) 
40–49 years . . . . . . . . . .  363  31.6  (26.3–37.4) 6.5 (4.2–9.5) 4.9 (2.9– 7.6) *2.7 (1.0–5.8) ** ** ** ** 
50–59 years . . . . . . . . . .  328  44.1  (38.5–49.8) 15.8 (11.1–21.5) 9.2 (6.2–12.9) 5.5 (2.7–9.8) *3.2 (1.5–6.0) ** ** ** 
60–69 years . . . . . . . . . .  287  57.6  (51.0–64.1) 27.8 (22.7–33.4) 20.6 (16.0–25.7) 14.9 (11.0–19.6) 7.6 (4.8–11.3) 3.3 (1.5–6.0) *1.4 (0.4–3.5) ** 
70 years and older . . . . . .  498  69.7  (65.5–73.7) 44.0 (39.6–48.5) 35.9 (31.7–40.3) 29.2 (25.3–33.4) 21.1 (17.6–25.0) 10.5 (8.0–13.6) 5.8 (3.7–8.7) 4.1 (2.5–6.4) 
70–79 years . . . . . . . . .  295  67.2  (61.5–72.5) 41.9 (36.2–47.7) 34.3 (28.9–40.0) 27.3 (22.3–32.8) 19.0 (14.7–23.9) 8.2 (4.9–12.6) 4.3 (2.2–7.4) *3.3 (1.5–6.3) 
80 years and older . . . . .  203  76.4  (68.6–83.1) 49.6 (41.7–57.6) 40.0 (32.2–48.3) 34.3 (27.7–41.3) 26.6 (19.8–34.4) 16.8 (11.9–22.7) 9.8 (5.4–16.1) 6.1 (3.0–10.8) 
Non–Hispanic black 
40 years and older . . . . . . .  435  45.7  (40.1–51.3) 19.0 (14.6–24.1) 12.5 (9.2–16.3) 9.5 (6.6–13.2) 7.8 (5.2–11.1) 4.3 (2.6–6.7) 3.0 (1.6–5.1) *1.9 (0.9–3.7) 
40–49 years . . . . . . . . . .  174  33.7  (26.7–41.2) *5.9 (2.2–12.5) ** ** ** ** ** ** 
50–59 years . . . . . . . . . .  101  47.4  (35.6–59.3) 24.2 (16.3–33.8) 13.9 (7.8–22.2) *8.5 (3.7–16.3) *7.9 (3.2–15.7) ** ** ** 
60–69 years . . . . . . . . . .  99  68.3  (58.2–77.3) 35.7 (26.3–45.9) 26.5 (18.2–36.4) 21.3 (13.7–30.7) 16.6 (9.1–26.7) *9.8 (4.3–18.5) *9.1 (3.6–18.0) *5.7 (2.0–12.3) 
70 years and older . . . . . .  61  70.8  (56.8–82.4) 47.9 (33.8–62.3) 46.2 (31.1–61.9) 43.6 (29.1–58.9) 37.2 (24.8–51.0) 20.0 (10.8–32.2) *12.7 (4.9–25.5) ** 
* Relative standard error 30–40 percent.

** Relative standard error greater than 40 percent, and the value was suppressed.

1All men includes sample persons of ‘‘other’’ race-ethnicity, but they are not shown separately.
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Table 5. Distribution of percent free PSA by total PSA for different age groups 
Age group and Percent Percent Estimated 
Total PSA free PSA of men population 
(ng/mL) (percent) Number (95% CI) (95% CI)2 
All men1 
Total  . . . . . . . . . . . . . . . . . . .  Total  2,546  100.0 57,609,000 
≤15 259 9.2 (7.6–11.0) 5,305,000 (4,391,000–6,339,000) 
>15–25 714 28.0 (25.8–30.3) 16,136,000 (14,889,000–17,430,000) 
>25 1,573 62.8 (59.6–65.9) 36,168,000 (34,319,000–37,971,000) 
0 to  <2.5  . . . . . . . . . . . . . . . .  Total  2,077  86.9  (85.5–88.3) 50,091,000 (49,234,000–50,890,000) 
≤15 121 5.0 (3.9–6.4) 2,898,000 (2,252,000–3,663,000) 
>15–25 543 23.1 (21.0–25.3) 13,282,000 (12,071,000–14,553,000) 
>25 1,413 58.9 (55.9–61.8) 33,911,000 (32,219,000–35,576,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  469  13.1  (11.7–14.5) 7,519,000 (6,720,000–8,376,000) 
2.5 to <4.0  . . . . . . . . . . . . . . .  Total  224  6.9  (5.8–8.0) 3,960,000 (3,361,000–4,629,000) 
≤15 47 1.5 (1.0–2.2) 867,000 (555,000–1,290,000) 
>15–25 91 2.9 (2.3–3.7) 1,681,000 (1,304,000–2,132,000) 
>25 86 2.4 (1.9–3.1) 1,411,000 (1,086,000–1,802,000) 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  245  6.2  (5.2–7.2) 3,559,000 (3,012,000–4,170,000) 
4.0 to <10  . . . . . . . . . . . . . . .  Total  195  5.1  (4.2–6.1) 2,929,000 (2,413,000–3,517,000) 
≤15 58 1.9 (1.3–2.8) 1,107,000 (731,000–1,605,000) 
>15–25 67 1.8 (1.3–2.4) 1,020,000 (730,000–1,386,000) 
>25 70 1.4 (1.0–1.9) 802,000 (561,000–1,110,000) 
10.0+  . . . . . . . . . . . . . . . . . .  Total  50  1.1  (0.7–1.6) 630,000 (419,000–909,000) 
≤15 33 0.8 (0.5–1.2) 433,000 (261,000–673,000) 
>15–25 13 *0.3 (0.1–0.6) *153,000 (60,000–318,000) 
>25 4 ** ** 
40–49 years 
Total  . . . . . . . . . . . . . . . . . . .  Total  747  100.0 21,363,000 
≤15 59 8.4 (6.4–10.7) 1,786,000 (1,365,000–2,285,000) 
>15–25 204 27.4 (23.4–31.8) 5,859,000 (4,993,000–6,787,000) 
>25 484 64.2 (59.4–68.8) 13,718,000 (12,686,000–14,707,000) 
0 to  <2.5  . . . . . . . . . . . . . . . .  Total  718  95.8  (93.7–97.3) 20,464,000 (20,021,000–20,793,000) 
≤15 48 6.5 (4.8–8.6) 1,396,000 (1,028,000–1,844,000) 
>15–25 189 25.3 (21.3–29.7) 5,406,000 (4,542,000–6,342,000) 
>25 481 64.0 (59.3–68.5) 13,663,000 (12,660,000–14,625,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  29  4.2  (2.7–6.3) 899,000 (570,000–1,341,000) 
2.5 to <4.0  . . . . . . . . . . . . . . .  Total  20  2.5  (1.5–3.9) 540,000 (326,000–838,000) 
>25 17 2.3 (1.3–3.6) 484,000 (283,000–770,000) 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  9  *1.7  (0.6–3.7) *359,000 (129,000–787,000) 
4.0 to <10.0  . . . . . . . . . . . . . .  Total  8  **  **  
10.0+  . . . . . . . . . . . . . . . . . .  Total  1  **  **  
50–59 years 
Total  . . . . . . . . . . . . . . . . . . .  Total  546  100.0 16,373,000 
≤15 60 10.0 (7.3–13.4) 1,640,000 (1,189,000–2,188,000) 
15–25 171 29.5 (24.9–34.4) 4,831,000 (4,078,000–5,639,000) 
25 315 60.5 (56.2–64.6) 9,902,000 (9,201,000–10,585,000) 
0 to  <2.5  . . . . . . . . . . . . . . . .  Total  487  90.0  (86.9–92.6) 14,733,000 (14,226,000–15,155,000) 
≤15 32 5.3 (3.4–7.7) 866,000 (564,000–1,264,000) 
15–25 147 25.6 (21.4–30.2) 4,197,000 (3,510,000–4,943,000) 
25 308 59.1 (54.8–63.2) 9,671,000 (8,974,000–10,351,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  59  10.0  (7.4–13.1) 1,640,000 (1,218,000–2,147,000) 
2.5 to <4.0  . . . . . . . . . . . . . . .  Total  36  6.2  (4.3–8.6) 1,013,000 (701,000–1,408,000) 
≤25 31 4.9 (3.0–7.5) 809,000 (499,000–1,231,000) 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  23  3.8  (2.3–5.9) 627,000 (379,000–970,000) 
4.0 to <10.0  . . . . . . . . . . . . . .  Total  18  3.0  (1.6–5.1) 497,000 (265,000–842,000) 
≤25 16 2.9 (1.4–5.1) 469,000 (231,000–841,000) 
10.0+  . . . . . . . . . . . . . . . . . .  Total  5  **  **  
See footnotes at end of table. 
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Table 5. Distribution of percent free PSA by total PSA for different age groups—Con. 
Age group and Percent Percent Estimated 
Total PSA free PSA of men population 
(ng/mL) (percent) Number (95% CI) (95% CI)2 
60–69 years 
Total  . . . . . . . . . . . . . . . . . . .  Total  555  100.0 9,932,000 
≤15 57 8.2 (6.0–10.8) 812,000 (594,000–1,078,000) 
>15%–25 173 30.8 (25.8–36.3) 3,064,000 (2,559,000–3,605,000) 
>25 325 61.0 (55.0–66.8) 6,056,000 (5,458,000–6,631,000) 
0  to  2.5  . . . . . . . . . . . . . . . . .  Total  439  79.8  (75.9–83.2) 7,921,000 (7,543,000–8,264,000) 
≤15 20 *2.7 (1.2–5.1) *271,000 (123,000–511,000) 
15%–25 126 22.5 (18.8–26.6) 2,234,000 (1,864,000–2,639,000) 
>25 293 54.5 (49.6–59.4) 5,416,000 (4,926,000–5,901,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  116  20.2  (16.8–24.1) 2,011,000 (1,668,000–2,389,000) 
2.5  to  4.0  . . . . . . . . . . . . . . . .  Total  61  12.2  (8.9–16.2) 1,212,000 (883,000–1,609,000) 
≤25 39 7.3 (4.6–10.8) 722,000 (456,000–1,077,000) 
>25 22 4.9 (2.7–8.2) 489,000 (265,000–817,000) 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  55  8.0  (5.9–10.6) 799,000 (588,000–1,056,000) 
4.0  to  10.0  . . . . . . . . . . . . . . .  Total  43  7.0  (5.0–9.4) 691,000 (495,000–934,000) 
≤25 35 5.5 (3.7–7.9) 551,000 (367,000–789,000) 
>25 8 *1.4 (0.5–3.0) *141,000 (53,000–300,000) 
10.0+  . . . . . . . . . . . . . . . . . .  Total  12  *1.1  (0.4–2.3) *108,000 (40,000–233,000) 
≤25 10 *1.0 (0.3–2.2) *98,000 (34,000–220,000) 
70–79 years 
Total  . . . . . . . . . . . . . . . . . . .  Total  447  100.0 6,817,000 
≤15 51 10.6 (6.8–15.5) 720,000 (463,000–1,054,000) 
>15%–25 105 22.5 (17.0–28.8) 1,533,000 (1,160,000–1,961,000) 
>25 291 66.9 (58.3–74.8) 4,563,000 (3,974,000–5,100,000) 
0  to  2.5  . . . . . . . . . . . . . . . . .  Total  288  64.9  (60.3–69.4) 4,427,000 (4,112,000–4,729,000) 
≤25 67 14.6 (9.6–20.8) 993,000 (656,000–1,416,000) 
>25 221 50.4 (43.8–57.0) 3,435,000 (2,983,000–3,885,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  159  35.1  (30.6–39.7) 2,390,000 (2,088,000–2,705,000) 
2.5  to  4.0  . . . . . . . . . . . . . . . .  Total  71  15.6  (12.4–19.3) 1,063,000 (842,000–1,316,000) 
≤25 36 6.8 (4.0–10.5) 461,000 (276,000–716,000) 
>25 35 8.8 (6.1–12.4) 602,000 (412,000–842,000) 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  88  19.5  (15.5–23.9) 1,326,000 (1,059,000–1,627,000) 
4.0  to  10.0  . . . . . . . . . . . . . . .  Total  73  16.2  (12.4–20.7) 1,105,000 (842,000–1,410,000) 
≤25 40 9.1 (5.6–13.6) 618,000 (384,000–930,000) 
>25 33 7.1 (4.9–10.0) 486,000 (333,000–680,000) 
10.0+  . . . . . . . . . . . . . . . . . .  Total  15  3.3  (1.6–5.8) 222,000 (111,000–394,000) 
≤25 13 2.7 (1.4–4.6) 181,000 (93,000–316,000) 
80 years and above 
Total  . . . . . . . . . . . . . . . . . . .  Total  251  100.0 3,125,000 
≤15 32 12.9 (8.0–19.3) 403,000 (249,000–604,000) 
>15%–25 61 25.7 (20.4–31.5) 802,000 (636,000–985,000) 
>25 158 61.5 (53.9–68.6) 1,921,000 (1,686,000–2,144,000) 
0 to  <2.5  . . . . . . . . . . . . . . . .  Total  145  58.0  (50.1–65.7) 1,814,000 (1,566,000–2,052,000) 
≤25 35 14.4 (10.3–19.4) 451,000 (323,000–606,000) 
>25 110 43.6 (37.2–50.2) 1,363,000 (1,162,000–1,568,000) 
2.5+  . . . . . . . . . . . . . . . . . . .  Total  106  42.0  (34.3–49.9) 1,311,000 (1,073,000–1,559,000) 
2.5 to <4.0  . . . . . . . . . . . . . . .  Total  36  12.9  (9.1–17.7) 405,000 (283,000–554,000) 
≤25 15 5.3 (2.7–9.3) 167,000 (85,000–292,000) 
>25 21 7.6 (4.4–12.1) 238,000 (137,000–378,000 
4.0+  . . . . . . . . . . . . . . . . . . .  Total  70  29.0  (22.4–36.4) 907,000 (700,000–1,136,000) 
4.0 to <10.0  . . . . . . . . . . . . . .  Total  53  22.7  (17.2–29.0) 709,000 (537,000–907,000) 
≤25 26 12.5 (7.8–18.5) 389,000 (245,000–577,000) 
>25 27 10.3 (6.4–15.3) 320,000 (200,000–479,000) 
10.0+  . . . . . . . . . . . . . . . . . .  Total  17  6.3  (3.3–10.8) 197,000 (103,000–336,000) 
≤25 17 6.3 (3.3–10.8) 197,000 (103,000–336,000) 
* Relative standard error 30–40 percent. 
** Relative standard error is greater than 40 percent, and the value was suppressed. 
1All men includes sample persons of ‘‘other’’ race-ethnicity, but they are not shown separately. 
2Estimated population and 95% confidence interval are rounded to nearest 1,000. 
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